Publication date: 2 November 2017
Source:Cell Stem Cell, Volume 21, Issue 5
Author(s): Roger A. Barker, Malin Parmar, Lorenz Studer, Jun Takahashi
Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.
Teaser
Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.http://ift.tt/2z6YLc1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου